TCR/BCR profiling using enrichment with pools of capture probes
This present disclosure relates to systems, methods, and compositions useful for profiling T cell receptor (TCR) and B cell receptor (BCR) repertoire using next-generation sequencing (NGS) methods. The present disclosure also relates to systems and methods for diagnosing, treating, or predicting infection, disease, medical conditions, therapeutic outcome, or therapeutic efficacy based on the TCR/BCR profile data from a subject in need thereof.
1. A method of determining the TCR/BCR profile of a patient who has cancer, the method comprising:
a) isolating RNA from a cancerous sample from the patient;
b) enriching the isolated RNA for TCR/BCR genes using a set of TCR/BCR hybrid-capture probes and enriching for a targeted whole transcriptome panel using a set of hybrid-capture probes;
c) determining the sequence of the RNA of (b) to generate sequencing data; and
d) analyzing the sequencing data to determine the TCR/BCR profile of the patient,
wherein the set of TCR/BCR hybrid-capture probes comprises a first pool comprising TCR constant region probes, a second pool comprising TCR non-constant region probes, a third pool comprising BCR constant region probes, a fourth pool comprising BCR non-constant region probes, and wherein a fifth pool comprises the transcriptome hybrid-capture probes.
2. The method of claim 1 , wherein the ratio of the first pool, second pool, third pool, and fourth pool within the set is 1:2.5:100:100.
3. The method of claim 1 , wherein the ratio of the first pool, second pool, third pool, fourth pool, and fifth pool within the set is 1:2.5:100:100:10.
4. The method of claim 3 , wherein 2% or less of the reads in the sequencing data map to TCR/BCR genes.
5. The method of claim 1 , wherein the sample is a blood sample, and the cancer is a heme cancer or a blood cancer.
6. The method of claim 1 , further comprising comparing the patient's TCR/BCR profile to a TCR/BCR control profile; wherein the control profile comprises an earlier TCR/BCR profile of the patient.
7. A method of identifying TCR/BCR non-constant region sequences that are enriched in a cohort of patients with a cancer, the method comprising:
a) isolating RNA from a sample from each patient in the cohort;
b) enriching the isolated RNA for TCR/BCR genes using a set of TCR/BCR hybrid-capture probes and enriching for a targeted whole transcriptome panel using a set of transcriptome hybrid-capture probes;
c) determining the sequence of the RNA of (b) to generate sequencing data;
d) analyzing the sequencing data to determine the TCR/BCR profile of the patients in the cohort; and
e) identifying TCR/BCR non-constant region sequences that are enriched in the cohort as compared to a control group without the cancer,
wherein the set of hybrid-capture probes comprises a first pool of TCR constant region probes, a second pool of TCR non-constant region probes, a third pool of BCR constant region probes, and a fourth pool of BCR non-constant region probes, and wherein a fifth pool comprises the transcriptome hybrid-capture probes.
8. The method of claim 7 , wherein the ratio of the first pool, second pool, third pool, and fourth pool within the set is 1:2.5:100:100.
9. The method of claim 7 , wherein the ratio of the first pool, second pool, third pool, fourth pool, and fifth pool within the set is 1:2.5:100:100:10.
10. The method of claim 9 , wherein 2% or less of the reads in the sequencing data map to TCR/BCR genes.
11. The method of claim 7 , wherein the sample is a blood sample, and the cancer is a heme cancer or a blood cancer.
12. A method of determining the TCR/BCR profile of a cancer patient, the method comprising:
a) isolating RNA from a sample comprising cancer cells from the patient;
b) enriching the isolated RNA for TCR/BCR genes using a set of TCR/BCR hybrid-capture probes and enriching for a targeted whole transcriptome panel using a set of transcriptome hybrid-capture probes;
c) sequencing the enriched RNA of (b) to generate sequencing data; and
d) analyzing the sequencing data to determine the TCR/BCR profile of the patient,
wherein the set of TCR/BCR hybrid-capture probes comprises a first pool comprising BCR constant region probes, a second pool comprising BCR non-constant region probes, a third pool comprising TCR constant region probes, and a fourth pool comprising TCR non-constant region probes, wherein the ratio of the transcriptome hybrid-capture probes, first pool, second pool, third pool, and fourth pool is 10:1:2.5:100:100, wherein 2% or less of the reads in the sequencing data map to TCR/BCR genes.
13. The method of claim 1 , wherein the cancer is a solid tumor cancer, and the sample comprises a biopsy of the solid tumor.
14. The method of claim 7 , wherein the cancer is a solid tumor cancer, and the sample comprises a biopsy of the solid tumor.
15. The method of claim 12 , wherein the cancer is a blood or heme cancer, and the sample comprises a blood sample.
16. The method of claim 12 , wherein the cancer is a solid tumor cancer, and the sample comprises a biopsy of the solid tumor.
17. The method of claim 6 , wherein the control profile was obtained prior to a cancer immunotherapy regimen, and the patient's TCR/BCR profile was determined during or after the cancer immunotherapy regimen.
18. The method of claim 1 , wherein the patient's TCR/BCR profile is determined after a cancer immunotherapy regimen, the method further comprising comparing the patient's TCR/BCR profile to a control TCR/BCR profile, wherein the control TCR/BCR profile is derived from a subject diagnosed with the same cancer as the patient and that has been treated with the same immunotherapy regimen as the patient, with positive outcome.
19. The method of claim 1 , wherein the patient's TCR/BCR profile is determined after a cancer treatment regimen, the method further comprising comparing the patient's TCR/BCR profile to a control TCR/BCR profile, wherein the control TCR/BCR profile is derived from a subject diagnosed with the same cancer as the patient and that has been treated with the same cancer treatment regimen as the patient, with negative outcome.
20. The method of claim 7 , wherein the TCR/BCR profile is identified in the cohort of patients during a cancer immunotherapy regimen.
21. The method of claim 7 , wherein the TCR/BCR profile is identified in the cohort of patients after a cancer immunotherapy regimen.
22. The method of claim 7 , wherein the TCR/BCR profile is identified in the cohort of patients after a cancer immunotherapy regimen and during a recurrence of the cancer.
23. The method of claim 17 , wherein the immunotherapy regimen comprises CAR-T cells, the method further comprising identifying engraftment of the CAR-T cells in the patient.